GPX4 and GPX7 over-expression in human hepatocellular carcinoma tissues

European Journal of Histochemistry

Volumn 59, Issue 4, 2015, Pages 5-10

  Guerriero, E ^a   Capone, F ^a   Accardo, M ^b   Sorice, A ^a   Costantini, M ^c   Colonna, G ^b   Castello, G ^a   Costantini, Susan ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c STAZIONE ZOOLOGICA ANTON DOHRN   (Italy)

Author keywords

GPX4; GPX7; Hepatocellular carcinoma; Immunohistochemistry; RT qPCR

Indexed keywords

GLUTATHIONE PEROXIDASE; GPX7 PROTEIN, HUMAN; PEROXIDASE; PHOSPHOLIPID-HYDROPEROXIDE GLUTATHIONE PEROXIDASE; TUMOR MARKER; TUMOR PROTEIN;

AGED; BIOSYNTHESIS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE PEROXIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PEROXIDASES;

EID: 84949560610     PISSN: 1121760X     EISSN: 20388306     Source Type: Journal    
DOI: 10.4081/ejh.2015.2540     Document Type: Article

References (25)

1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer, Lyon; 2013.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
3. Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, Maio P, et al. Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One 2012; 7: e39486.
4. El Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-S34.
5. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.
6. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
7. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-7.
8. Llovet JM, Fuster J, Bruix J. Intention-totreat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
9. Theunissen W, Fanni D, Nemolato S, Di Felice E, Cabras T, Gerosa C, et al. Thymosin beta 4 and thymosin beta 10 expression in hepatocellular carcinoma. Eur J Histochem 2014; 58: 2242.
10. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160: 1-40.
11. Bellinger FP, Raman AV, Reeves MA, Berry MJ. Regulation and function of selenoproteins in human disease. Biochem J 2009; 422: 11-22.
12. Raucci R, Colonna G, Guerriero E, Capone F, Accardo M, Castello G, et al. Structural and functional studies of the human selenium binding protein-1 and its involvement in hepatocellular carcinoma. Biochim Biophys Acta 2011; 1814: 513-22.
13. Di Stasio M, Volpe MG, Colonna G, Nazzaro M, Polimeno M, Scala S, et al. A possible predictive marker of progression for hepatocellular carcinoma. Oncol Lett 2011; 2: 1247-51.
14. Guerriero E, Accardo M, Capone F, Colonna G, Castello G, Costantini S. Assessment of the Selenoprotein M (SELM) over-expression on human hepatocellular carcinoma tissues by immunohistochemistry. Eur J Histochem 2014; 58: 2433.
15. Costantini S, Di Bernardo G, Cammarota M, Castello G, Colonna G. Gene expression signature of human HepG2 cell line. Gene 2013; 518: 335-345.
16. Guariniello S, Di Bernardo G, Colonna G, Cammarota M, Castello G, Costantini S. Evaluation of the selenotranscriptome expression in two hepatocellular carcinoma cell lines. Anal Cell Pathol (Amst) 2015; 2015: 419561.
17. Brigelius-Flohé R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta 2013; 1830: 3289-303.
18. Scheerer P, Borchert A, Krauss N, Wessner H, Gerth C, Höhne W, et al. Structural basis for catalytic activity and enzyme polymerization of phospholipid hydroperoxide glutathione peroxidase-4 (GPX4). Bio-chemistry 2007; 46: 9041-9.
19. Yagublu V, Arthur JR, Babayeva SN, Nicol F, Post S, Keese M. Expression of selenium-containing proteins in human colon carcinoma tissue. Anticancer Res 2011; 31: 2693-8.
20. Bermano G, Smyth E, Goua M, Heys SD, Wahle KW. Impaired expression of glutathione peroxidase-4 gene in peripheral blood mononuclear cells: a biomarker of increased breast cancer risk. Cancer Biomark 2010; 7: 39-46.
21. Pellatt AJ, Wolff RK, John EM, Torres-Mejia G, Hines LM, Baumgartner KB, et al. SEPP1 influences breast cancer risk among women with greater native american ancestry: the breast cancer health disparities study. PLoS One 2013; 8: e80554.
22. Van Blarigan EL, Ma J, Kenfield SA, Stampfer MJ, Sesso HD, Giovannucci EL, et al. Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival. Cancer Epidemiol Biomarkers Prev 2014; 23: 1037-46.
23. Brault C, Lévy P, Duponchel S, Michelet M, Sallé A, Pécheur EI, et al. Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity. Gut 2014; pii: gutjnl-2014-307904.
24. Peng DF, Hu TL, Soutto M, Belkhiri A, El-Rifai W. Glutathione peroxidase 7 suppresses bile salt-induced expression of pro-inflammatory cytokines in Barrett's carcinogenesis. J Cancer 2014; 5: 510-7.
25. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during col.